Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data (original) (raw)

• Hodson, R. Precision medicine. Nature 537, S49 (2016).
  Article CAS PubMed Google Scholar
• Morash, M., Mitchell, H., Beltran, H., Elemento, O. & Pathak, J. The role of next-generation sequencing in precision medicine: a review of outcomes in oncology. J. Pers. Med. 8, E30 (2018).
  Article PubMed Google Scholar
• Garraway, L. A., Verweij, J. & Ballman, K. V. Precision oncology: an overview. J. Clin. Oncol. 31, 1803–1805 (2013).
  Article PubMed Google Scholar
• Marquart, J., Chen, E. Y. & Prasad, V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 4, 1093–1098 (2018).
  Article PubMed PubMed Central Google Scholar
• Sun, L. et al. Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer. JAMA Oncol. 7, 937–939 (2021).
  Article PubMed PubMed Central Google Scholar
• Raponi, M., Winkler, H. & Dracopoli, N. C. KRAS mutations predict response to EGFR inhibitors. Curr. Opin. Pharmacol. 8, 413–418 (2008).
  Article CAS PubMed Google Scholar
• Hernán, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758–764 (2016).
  Article PubMed PubMed Central Google Scholar
• Danaei, G., García Rodríguez, L. A., Cantero, O. F., Logan, R. W. & Hernán, M. A. Electronic medical records can be used to emulate target trials of sustained treatment strategies. J. Clin. Epidemiol. 96, 12–22 (2018).
  Article PubMed PubMed Central Google Scholar
• Liu, R. et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592, 629–633 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Singal, G. et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA 321, 1391–1399 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, Q., Gossai, A., Monroe, S., Nussbaum, N. C. & Parrinello, C. M. Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States. Health Serv. Res. 56, 1281–1287 (2021).
  Article PubMed PubMed Central Google Scholar
• Curtis, M. D. et al. Development and validation of a high-quality composite real-world mortality endpoint. Health Serv. Res. 53, 4460–4476 (2018).
  Article PubMed PubMed Central Google Scholar
• Carrigan, G. et al. Using electronic health records to derive control arms for early phase single-arm lung cancer trials: proof-of-concept in randomized controlled trials. Clin. Pharmacol. Ther. 107, 369–377 (2020).
  Article PubMed Google Scholar
• Suissa, S. Immortal time bias in pharmaco-epidemiology. Am. J. Epidemiol. 167, 492–499 (2008).
  Article PubMed Google Scholar
• Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300 (1995).
  Google Scholar
• Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P. & Olivier, M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157–2165 (2007).
  Article CAS PubMed Google Scholar
• Wolfer, A. et al. MYC regulation of a ‘poor-prognosis’ metastatic cancer cell state. Proc. Natl Acad. Sci. U. S. A. 107, 3698–3703 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, R., Choi, B. Y., Lee, M.-H., Bode, A. M. & Dong, Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in Cancer. EBioMedicine 8, 30–39 (2016).
  Article PubMed PubMed Central Google Scholar
• Cavanna, L., Citterio, C. & Orlandi, E. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget 10, 209–215 (2019).
  Article PubMed PubMed Central Google Scholar
• Mazieres, J. et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 0, 1321–1328 (2019).
  Article CAS Google Scholar
• Rossi, G. et al. Precision medicine for NSCLC in the Era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient. Cancers 12, E1125 (2020).
  Article PubMed CAS Google Scholar
• Guibert, N. et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer 137, 1–6 (2019).
  Article PubMed Google Scholar
• Tsao, M.-S. et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J. Clin. Oncol. 25, 5240–5247 (2007).
  Article PubMed Google Scholar
• Wang, W.-X. et al. TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. J. Thorac. Dis. 10, 2991–2998 (2018).
  Article PubMed PubMed Central Google Scholar
• Witkiewicz, A. K. et al. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin. Cancer Res. 18, 5110–5122 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ertel, A. et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 9, 4153–4163 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tanioka, M. et al. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer. Breast Cancer Res. Treat. 147, 513–525 (2014).
  Article CAS PubMed Google Scholar
• Chen, K., Quan, J., Yang, J. & Chen, Z. The potential markers of endocrine resistance among HR+/HER2+ breast cancer patients. Clin. Transl. Oncol. 22, 576–584 (2020).
  Article CAS PubMed Google Scholar
• Rastelli, F. & Crispino, S. Factors predictive of response to hormone therapy in breast cancer. Tumori 94, 370–383 (2008).
  Article PubMed Google Scholar
• de Bruin, E. C. et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 4, 606–619 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Hsu, C. P. et al. Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur. J. Surg. Oncol. 37, 140–147 (2011).
  Article CAS PubMed Google Scholar
• Carbuccia, N. et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 23, 2183–2186 (2009).
  Article CAS PubMed Google Scholar
• Endele, S. et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat. Genet. 42, 1021–1026 (2010).
  Article CAS PubMed Google Scholar
• Carvill, G. L. et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat. Genet. 45, 1073–1076 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Odogwu, L. et al. FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. Oncologist 23, 740–745 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Eng, C. BRAF mutation in colorectal cancer: an enigmatic target. J. Clin. Oncol. 39, 259–261 (2021).
  Article PubMed Google Scholar
• Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).
  Article CAS PubMed Google Scholar
• Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet Lond. Engl. 389, 67–76 (2017).
  Article CAS Google Scholar
• West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924–937 (2019).
  Article CAS PubMed Google Scholar
• Peters, S. et al. Phase II Trial of Atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J. Clin. Oncol. 35, 2781–2789 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265 (2017).
  Article PubMed Google Scholar
• Chakravarty, D. et al. OncoKB: A precision oncology knowledge base. JCO Precis. Oncol. 2017, 1–16 (2017).
  Google Scholar
• Kron, A. et al. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol. 29, 2068–2075 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, C. et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 470, 95–105 (2020).
  Article CAS PubMed Google Scholar
• McGough, S. F. et al. Penalized regression for left-truncated and right-censored survival data. Stat. Med. 40, 5487–5500 (2021).
  Article PubMed PubMed Central Google Scholar
• Dong, Z.-Y. et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 23, 3012–3024 (2017).
  Article CAS PubMed Google Scholar
• Okamoto, I. et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer 117, 14–19 (2018).
  Article PubMed Google Scholar
• Papillon-Cavanagh, S., Doshi, P., Dobrin, R., Szustakowski, J. & Walsh, A. M. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open 5, e000706 (2020).
  Article PubMed PubMed Central Google Scholar
• Frampton, G. M. et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023–1031 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• He, J. et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood 127, 3004–3014 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Woodhouse, R. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15, e0237802 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Carrigan, G. et al. An evaluation of the impact of missing deaths on overall survival analyses of advanced non-small cell lung cancer patients conducted in an electronic health records database. Pharmacoepidemiol. Drug Saf. 28, 572–581 (2019).
  Article PubMed PubMed Central Google Scholar
• André, F. et al. AACR project GENIE: Powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).
  Article Google Scholar